- $37.66m
- -$16.42m
- $20.60m
Brief: Scynexis Reports Third Quarter 2022 Financial Results
Scynexis Inc Expected To Post A Loss Of 50 Cents A Share: Earnings Preview
Brief: Pooled Data From The Pivotal Phase 3 Vanish Program Published In The Journal Of Women’S Health
Brief: Scynexis To Report Q3 Financial Results
Brief: Biopharma Veteran Ivor Macleod Joins Scynexis As Chief Financial Officer
Scynexis gains on positive fungal infection treatment trail data
Brief: Scynexis Presents Positive Interim Data Of Oral Ibrexafungerp For Severe Fungal Infections
U.S. STOCKS ON THE MOVE-Lam Research, Cyngn, Par Pacific
U.S. STOCKS ON THE MOVE-Vertiv, U.S. energy, Gold miners
Advisory: Alerts on Synexis and Knight-Swift withdrawn
Scynexis slips after strategic changes to develop vaginal infection drug
Brief: Scynexis Provides Corporate, Commercial And Research And Development Strategy Updates To Expand Market Potential For Its First-In-Class Antifungal
Brief: Scynexis Presents Positive Interim Data Of Ibrexafungerp For Refractory Candida Infections
Scynexis Inc Reports Results For The Quarter Ended In June: Earnings Summary
Brief: SCYNEXIS Reports Q2 Loss Per Share Of $0.31
Scynexis Inc Expected To Post A Loss Of 59 Cents A Share: Earnings Preview
Brief: Scynexis Presents Positive Data From Its Pivotal Phase 3 Candle Study Of Oral Ibrexafungerp For Prevention Of Recurrent Vaginal Yeast Infections During 2022 Idsog Annual Meeting
U.S. STOCKS ON THE MOVE-Scynexis, Sierra Wireless, CymaBay
Scynexis gains as FDA grants priority review for vaginal infection drug